<?xml version='1.0' encoding='utf-8'?>
<document id="31810914"><sentence text="New Chalcone Derivative Inhibits ABCB1 in Multidrug Resistant T-cell Lymphoma and Colon Adenocarcinoma Cells."><entity charOffset="4-12" id="DDI-PubMed.31810914.s1.e0" text="Chalcone" /></sentence><sentence text="Development of new potential drugs to overcome multidrug resistance to chemotherapy is a big challenge for cancer treatment" /><sentence text=" Attention is also given to the natural compounds and their derivatives" /><sentence text=" The study aimed at evaluating the impact of a new chalcone derivative (1C) on multidrug resistant cell lines, focusing on P-glycoprotein (P-gp, ABCB1) inhibition, as well as 1C-doxorubicin interaction in vitro"><entity charOffset="51-59" id="DDI-PubMed.31810914.s4.e0" text="chalcone" /><entity charOffset="175-189" id="DDI-PubMed.31810914.s4.e1" text="1C-doxorubicin" /><pair ddi="false" e1="DDI-PubMed.31810914.s4.e0" e2="DDI-PubMed.31810914.s4.e0" /><pair ddi="false" e1="DDI-PubMed.31810914.s4.e0" e2="DDI-PubMed.31810914.s4.e1" /></sentence><sentence text="" /><sentence text="Cytotoxic and antiproliferative effects of the 1C compound were assessed by thiazolyl blue tetrazolium bromide (MTT) method in mouse T-cell lymphoma and human colon adenocarcinoma cells expressing ABCB1"><entity charOffset="47-49" id="DDI-PubMed.31810914.s6.e0" text="1C" /><entity charOffset="91-110" id="DDI-PubMed.31810914.s6.e1" text="tetrazolium bromide" /><entity charOffset="112-115" id="DDI-PubMed.31810914.s6.e2" text="MTT" /><pair ddi="false" e1="DDI-PubMed.31810914.s6.e0" e2="DDI-PubMed.31810914.s6.e0" /><pair ddi="false" e1="DDI-PubMed.31810914.s6.e0" e2="DDI-PubMed.31810914.s6.e1" /><pair ddi="false" e1="DDI-PubMed.31810914.s6.e0" e2="DDI-PubMed.31810914.s6.e2" /><pair ddi="false" e1="DDI-PubMed.31810914.s6.e1" e2="DDI-PubMed.31810914.s6.e1" /><pair ddi="false" e1="DDI-PubMed.31810914.s6.e1" e2="DDI-PubMed.31810914.s6.e2" /></sentence><sentence text=" Alterations in ABCB1 activity were evaluated by rhodamine 123 accumulation assay using flow cytometry" /><sentence text=" Drug-drug interaction was studied using combination assay" /><sentence text="" /><sentence text="Our results confirmed antiproliferative, cytotoxic, as well as ABCB1 inhibitory potential of 1C in both tested ABCB1-expressing cancer cell lines"><entity charOffset="93-95" id="DDI-PubMed.31810914.s10.e0" text="1C" /></sentence><sentence text=" Furthermore, 1C displayed synergistic interaction with doxorubicin"><entity charOffset="56-67" id="DDI-PubMed.31810914.s11.e0" text="doxorubicin" /><entity charOffset="14-24" id="DDI-PubMed.31810914.s11.e1" text="1C" /><pair ddi="false" e1="DDI-PubMed.31810914.s11.e1" e2="DDI-PubMed.31810914.s11.e1" /><pair ddi="false" e1="DDI-PubMed.31810914.s11.e1" e2="DDI-PubMed.31810914.s11.e0" /></sentence><sentence text="" /><sentence text="Our results suggest the 1C chalcone derivative as a promising compound against resistant lymphoma and colon cancer, which could be used in monotherapy or in combination with other chemotherapeutics"><entity charOffset="24-35" id="DDI-PubMed.31810914.s13.e0" text="1C chalcone" /></sentence><sentence text="" /></document>